[1]华盛,欧梁,何瀚威,等.恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎临床研究[J].中国中医骨伤科杂志,2024,32(08):39-43+47.[doi:10.20085/j.cnki.issn1005-0205.240808 ]
　HUA Sheng,OU Liang,HE Hanwei,et al.Clinical Study on Efficacy of Internal and External Linkage of the Osteoking on the Treatment of Knee Osteoarthritis with Qizhi Xueyu Syndrome[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2024,32(08):39-43+47.[doi:10.20085/j.cnki.issn1005-0205.240808 ]
点击复制

恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎临床研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第32卷
期数:
2024年08期
页码:
39-43+47
栏目:
临床研究
出版日期:
2024-08-15

文章信息/Info

Title:
Clinical Study on Efficacy of Internal and External Linkage of the Osteoking on the Treatment of Knee Osteoarthritis with Qizhi Xueyu Syndrome
文章编号:
1005-0205(2024)08-0039-05
作者:
华盛1; 欧梁2; 何瀚威1; 刘科1; 白林寒1; 熊逸啸1; 汤祖宇1; 匡建军2△
1湖南中医药大学(长沙,410208)；2湖南省中医药研究院
Author(s):
HUA Sheng1; OU Liang2; HE Hanwei1; LIU Ke1; BAI Linhan1; XIONG Yixiao1; TANG Zuyu1; KUANG Jianjun2△
1Hunan University of Chinese Medicine,Changsha 410208,China; 2Hunan Academy of Chinese Medicine,Changsha 410006,China.
关键词:
膝骨关节炎;  气滞血瘀证;  恒古骨伤愈合剂;  中医定向透药疗法;  内外并用
Keywords:
knee osteoarthritis;  Qizhi Xueyu syndrome;  osteoking;  traditional Chinese medicine directional penetration;  both internal and external treatment
分类号:
R684.3
DOI:
10.20085/j.cnki.issn1005-0205.240808
文献标志码:
A
摘要:
目的:观察恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎的临床疗效。方法:从2022年9月至2023年9月收集120例气滞血瘀型膝骨关节炎患者,按随机数字表法分为联合组、透药组、口服组、对照组(各30例)。联合组予恒古骨伤愈合剂口服联合中医定向透药治疗,透药组予恒古骨伤愈合剂中医定向透药治疗,口服组予恒古骨伤愈合剂口服治疗,对照组予塞来昔布治疗,以12 d为1个疗程,治疗2个疗程。观察四组患者治疗前后临床疗效、视觉模拟量表(VAS)评分、西安大略和麦克马斯特大学(WOMAC)评分、中医证候评分、健康状况调查问卷(SF-36)评分及炎症因子水平变化。结果:治疗前,四组患者VAS评分、WOMAC评分、中医证候评分、SF-36评分及炎症因子比较,差异无统计学意义(P>0.05); 治疗后联合组临床疗效、VAS评分、WOMAC评分、中医证候评分、SF-36评分及炎症因子的改善效果优于对照组、透药组、口服组,差异有统计学意义(P<0.05)。结论:恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎疗效突出,在改善临床症状、降低炎症因子水平、提高患者生活质量等方面效果显著。
Abstract:
Objective:To observe the clinical efficacy of osteoking on the treatment of knee osteoarthritis with Qizhi Xueyu syndrome.Methods:120 patients with Qizhi Xueyu syndrome knee osteoarthritis from September 2022 to September 2023 were collected and divided into combination group,drug dialysis group,oral group and control group according to random number table method,with 30 cases in each group.In the combination group,osteoking was given orally combined with traditional Chinese medicine(TCM)directional penetration therapy; in the drug dialysis group,osteoking was treated with directional drug penetration treatment; in the oral group,osteoking was given orally,and the control group was treated with celecoxib.12 d as one course of treatment and 2 courses of treatment.The clinical efficacy,visual analogue scale(VAS)scores,Western Ontario and McMaster Universities(WOMAC)scores,TCM syndrome scores,36-Item Short Form Health Survey(SF-36)scores,and the level of inflammatory factors were observed before and after treatment in 4 groups.Results:There was no statistical difference in VAS scores,WOMAC scores,TCM syndrome scores,SF-36 scores and inflammatory factors among 4 groups before treatment(P>0.05).The VAS scores,WOMAC scores,TCM syndrome scores,SF-36 scores and inflammatory factors in combination group were better than those in control group,drug penetration group and oral group after treatment(P<0.05).Conclusion:Osteoking has outstanding therapeutic efficacy on Qizhi Xueyu syndrome knee osteoarthritis,which can improve clinical symptoms,reduce the level of inflammatory factors and improve the quality of life of patients.

参考文献/References:

[1] LIU Z F,ZHANG Y,LIU J,et al.Effect of traditional Chinese non-pharmacological therapies on knee osteoarthritis:a narrative review of clinical application and mechanism[J].Orthop Res Rev,2024,16:21-33.
[2] 王斌,邢丹,董圣杰,等.中国膝骨关节炎流行病学和疾病负担的系统评价[J].中国循证医学杂志,2018,18(2):134-142.
[3] YE Q Y,LIN Q,HU X L,et al.Efficacy and safety of combined Chinese and Western medicine in the treatment of knee osteoarthritis:a prospective,multicenter cohort study[J].Front Pharmacol,2023,14:1176980.
[4] 靳天,程志祥.膝骨关节炎非手术治疗的现状与思考[J].中华医学杂志,2021,101(43):3525-3527.
[5] 叶子丰,匡浩铭,沈琳玲,等.恒古骨伤愈合剂治疗神经根型颈椎病肝肾亏虚证临床研究[J].辽宁中医杂志,2023,50(4):64-67.
[6] 刘钦岱,匡浩铭,白林寒,等.恒古骨伤愈合剂定向透药联合塞来昔布胶囊口服治疗膝骨关节炎的临床研究[J].中医药导报,2023,29(4):84-87.
[7] 中华医学会骨科学分会关节外科学组,中国医师协会骨科医师分会骨关节炎学组,国家老年疾病临床医学研究中心(湘雅医院),等.中国骨关节炎诊疗指南(2021年版)[J].中华骨科杂志,2021,41(18):1291-1314.
[8] 中国中医药研究促进会骨伤科分会.膝骨关节炎中医诊疗指南(2020年版)[J].中医正骨,2020,32(10):1-14.
[9] 孙国丽,金瑛,胡雪蓉.耳穴压豆联合中医定向透药对全膝关节置换术后患者早期疼痛的干预研究[J].中华全科医学,2020,18(6):1010-1013.
[10] 国家食品药品监督管理局.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:349-353.
[11] ZHAO L,ZHOU S,WANG S,et al.Zhuifeng Tougu capsules in the treatment of knee osteoarthritis(cold dampness obstruction syndrome):a randomized,double blind,multicenter clinical study[J].Chin Med,2024,19(1):18.
[12] TONG B,CHEN H,WANG M,et al.Association of body composition and physical activity with pain and function in knee osteoarthritis patients:a cross-sectional study[J].BMJ Open,2024,14(1):e076043.
[13] 马骁,阎小萍,于辉,等.骨关节炎中医证候量化标准积分用于膝骨关节炎的研究[J].中日友好医院学报,2017,31(3):145-148.
[14] TAN B,YAN Y,ZHOU Q,et al.Kinesitherapy for knee osteoarthritis patients physical and psychological health based on “traditional Chinese exercise” management modalities:a systematic review and meta-analysis of randomized controlled trials[J].Orthop Surg,2024,16(1):3-16.
[15] 熊逸啸,华盛,汤祖宇,等.匡建军从筋骨肉并重论治膝骨关节炎[J].中医药导报,2023,29(12):173-176.
[16] 郑斌,梅伟,魏成建.中医治疗膝骨关节炎研究进展[J].湖北中医药大学学报,2016,18(2):114-117.
[17] 谭学松,匡浩铭,熊杰,等,恒古骨伤愈合剂治疗肝肾亏虚型膝骨关节炎30例[J].中国中医骨伤科杂志,2021,29(8):44-47.
[18] 高帅,周峻,梁志,等.基于真实世界的恒古骨伤愈合剂治疗638例膝骨关节炎患者临床特征及用药规律分析[J].中国中医药信息杂志,2023,30(10):157-162.
[19] 何霞,王雷.炎性因子及信号通路在膝骨关节炎中的研究进展[J].河北医药,2023,45(5):756-760.
[20] 王迷娜,刘璐,赵洛鹏,等.膝骨关节炎炎性因子及信号通路的研究进展[J].中国骨伤,2020,33(4):388-392.
[21] 梁志,周峻,全锐,等.恒古骨伤愈合剂联合非甾体抗炎药治疗膝骨关节炎的临床观察[J].中国实验方剂学杂志,2023,29(24):80-86.
[22] 王永强,龚海洋,赵磊,等.深刺温针灸联合中医定向透药疗法治疗寒湿痹阻型椎动脉型颈椎病48例[J].环球中医药,2022,15(10):1954-1957.
[23] 何瀚威,匡浩铭,白林寒,等.恒古骨伤愈合剂内外联动治疗膝骨关节炎30例临床观察[J].中医药导报,2023,29(8):66-70.

备注/Memo

备注/Memo:
基金项目:湖南省自然科学基金项目(2023JJ60118) 长沙市科技局重点项目(kh2201063) 湖南省中医药研究院院级课题项目(202129) △通信作者 E-mail:13786165656@163.com
更新日期/Last Update: 2024-08-05